

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Posaconazole

May 20, 2025

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Posaconazole

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current			Revision		
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozone, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, finerenone, azelnidipine, olmesartan medoxomil/azelnidipine, lurasidone hydrochloride, blonanserin, triazolam, rivaroxaban</p>			<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozone, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, finerenone, <u>eplerenone</u>, azelnidipine, olmesartan medoxomil/azelnidipine, lurasidone hydrochloride, blonanserin, triazolam, rivaroxaban</p>		
<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>			<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Finerenone	The effect of <u>finerenone</u> may be enhanced.	The plasma concentration of <u>finerenone</u> is expected to increase due to inhibition of CYP3A4 by co-administration with posaconazole.	Finerenone <u>Eplerenone</u>	The effect of <u>these drugs</u> may be enhanced.	The plasma concentration of <u>these drugs</u> is expected to increase due to inhibition of CYP3A4 by co-administration with posaconazole.